PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLonafarnib
Zokinvy(lonafarnib)
Zokinvy (lonafarnib) is a small molecule pharmaceutical. Lonafarnib was first approved as Zokinvy on 2020-11-20. It has been approved in Europe to treat laminopathies and progeria. It is known to target GTPase HRas, GTPase KRas, and GTPase NRas.
Download report
Favorite
FDA Novel Drug Approvals 2020
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Zokinvy
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lonafarnib
Tradename
Company
Number
Date
Products
ZOKINVYSentynl TherapeuticsN-213969 RX2020-11-20
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lonafarnibNew Drug Application2020-12-04
zokinvyNew Drug Application2024-04-04
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
LONAFARNIB, ZOKINVY, EIGER BIOPHARMS
2027-11-20ODE-324
2025-11-20NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Lonafarnib, Zokinvy, Eiger Biopharms
78385312024-07-26U-3070
88283562023-10-17U-3070
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AX: Various alimentary tract and metabolism products
— A16AX20: Lonafarnib
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis dD003699EFO_0007304——82——10
HepatitisD006505HP_0012115K75.9—82——10
Chronic hepatitis dD019701———72——9
Hepatitis aD006506EFO_0007305B15—41——5
Lung neoplasmsD008175HP_0100526C34.90211——3
LeukemiaD007938—C95111——3
SyndromeD013577———21——3
Myelodysplastic syndromesD009190—D46——1——1
Myelomonocytic leukemia chronicD015477—C93.1——1——1
Myelomonocytic leukemia juvenileD054429—C93.3——1——1
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5033——16
ProgeriaD011371EFO_0000671E34.814——15
GlioblastomaD005909EFO_0000515—21———3
Head and neck neoplasmsD006258——21———3
Prostatic neoplasmsD011471—C6121———2
Ovarian neoplasmsD010051EFO_0003893C5612———2
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—11———2
Myeloid leukemiaD007951—C9211———2
Chronic hepatitisD006521—K73.9—2———2
Squamous cell carcinomaD002294——11———2
Show 12 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——2————2
GliomaD005910EFO_0000520—2————2
GliosarcomaD018316——2————2
Central nervous system neoplasmsD016543——2————2
Nervous system neoplasmsD009423——2————2
NeoplasmsD009369—C802————2
SarcomaD012509——1————1
AstrocytomaD001254EFO_0000271—1————1
RecurrenceD012008——1————1
Supratentorial neoplasmsD015173—C71.01————1
Show 1 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LaminopathiesD000083083——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLonafarnib
INNlonafarnib
Description
Lonafarnib is a 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor. It has a role as an antineoplastic agent and an EC 2.5.1.58 (protein farnesyltransferase) inhibitor.
Classification
Small molecule
Drug classfarnesyl transferase inhibitor
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1
Identifiers
PDB—
CAS-ID193275-84-2
RxCUI—
ChEMBL IDCHEMBL298734
ChEBI ID—
PubChem CID148195
DrugBankDB06448
UNII IDIOW153004F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HRAS
HRAS
KRAS
KRAS
Organism
Homo sapiens
Gene name
HRAS
Gene synonyms
HRAS1
NCBI Gene ID
3265
Protein name
GTPase HRas
Protein synonyms
c-H-ras, c-has/bas p21 protein, GTP- and GDP-binding peptide B, H-Ras-1, Ha-Ras, Ha-Ras1 proto-oncoprotein, Harvey rat sarcoma viral oncogene homolog, Harvey rat sarcoma viral oncoprotein, p19 H-RasIDX protein, p21ras, Ras family small GTP binding protein H-Ras, transformation gene: oncogene HAMSV, Transforming protein p21, v-Ha-ras Harvey rat sarcoma viral oncogene homolog
Uniprot ID
Q9UCE2
Mouse ortholog
Hras (15461)
GTPase HRas (Q811B9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,480 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
97 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use